A Preliminary Study on the Efficacy and Safety of a Novel Digital Therapeutic Device: A Randomized Clinical Trial in South Korean Pediatric Patients With Attention-Deficit/Hyperactivity Disorder

CONCLUSION: ADAM-101 as an adjunct to pharmacotherapy showed preliminary benefits in clinician- and parent-rated symptom severity and auditory attention, without significant safety concerns. Larger confirmatory trials are warranted.

via https://pubmed.ncbi.nlm.nih.gov/42289874/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1L37KAMf2b_g4WEK3LmdFuKZu9pO3cN7u4ZmO9PPCPeBLMIw1q&fc=None&ff=20260626010905&v=2.20.0